Cancer Therapeutic and Diagnostic Products Discovered from the Protective Immune Responses of Patients

MabVax is a clinical stage biotechnology company. We have discovered and are developing novel human antibody based products for the diagnosis and treatment of solid tumor cancers.

About MabVax Therapeutics


MabVax Discovery Platform

MabVax Discovery Platform

We have created a platform technology to discover antibodies from patient immune responses against their cancers.

View Platform
Clinical Development

Clinical Development

Our portfolio includes fully human antibodies that are being developed to address unmet medical needs in several difficult to treat cancers such as pancreatic, lung, sarcoma, ovarian, and breast cancer.

View Product Pipeline

Investor Relations

MabVax Therapeutics Holdings, Inc. NASDAQ: MBVX
Day Range
52 Week Range

Sign Up for Email Alerts

Stay informed and receive company updates straight to your inbox.

Sign Up Now